Third Harmonic Bio is a clinical-stage biopharmaceutical company developing THB335, a highly selective oral KIT inhibitor targeting mast cells to provide symptomatic relief for dermal, respiratory, and gastrointestinal inflammatory diseases. This approach aims to enhance clinical efficacy and improve patient outcomes in managing a range of inflammatory disorders.
Funding
$105M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVGAFounders
Product
Problem
Many inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract lack effective treatments that provide broad symptomatic relief. Current therapies often fail to adequately target the underlying mast cell activation, leading to suboptimal clinical outcomes.
Solution
Third Harmonic Bio is developing THB335, an oral KIT inhibitor designed to selectively target mast cells and address the root cause of inflammation in dermal, respiratory, and gastrointestinal disorders. By inhibiting the KIT receptor, THB335 aims to suppress mast cell activation and the subsequent release of inflammatory mediators, potentially leading to significant symptomatic improvement across a range of inflammatory conditions. The oral formulation offers a convenient route of administration for patients requiring chronic treatment.
Target Audience
The primary target audience includes patients suffering from dermal, respiratory, and gastrointestinal inflammatory diseases, as well as physicians specializing in dermatology, pulmonology, and gastroenterology.
Features
- Highly selective oral KIT inhibitor
- Designed to target mast cells, key drivers of inflammation
- Potential application across a range of inflammatory diseases: chronic urticaria, severe asthma
- Convenient oral administration